The second generation kit is designed to measure blood levels of HA in order to evaluate the degree of liver fibrosis and cirrhosis in chronic liver disease.
Corgenix president and CEO Douglass Simpson said the CE marking of their automated HA product allows them to market the product in Europe through their distribution partner ELITech.
"We have a very active development program with ELITech and over the next few years we will bring additional new products to the world markets," Simpson said.
Corgenix and ELITech have entered into joint product development agreement in 2010, under which they have developed the first automated HA product.
ELITech supplies the first automated HA product in Europe, where as in US it is available for research purposes only through Corgenix.
